SNGX Share Price | Soligenix, Inc. Stock Analysis & Recommendation

Q: How big is Soligenix, Inc.?

Market Cap: As of Jun 18, Soligenix, Inc. has a market capitalization of 5.88 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Soligenix, Inc. reported net sales of 0.00 million and a net profit of -9.59 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 4.12 million and total assets of 8.97 million.

Q: What does Soligenix, Inc. do?

Overview:Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot:Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025)Market cap: USD 5.88 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -2.00Return on Equity: -276.72%Price to Book: 1.63Contact Details:Address: 29 Emmons Dr Ste B10, PRINCETON NJ: 08540-5950Tel: 1 609 5388200Website: https://www.soligenix.com/

Q: Is Soligenix, Inc. overvalued or undervalued?

As of 13 August 2021, the valuation grade for Soligenix, Inc. has moved from risky to does not qualify, indicating a shift in the assessment of its financial health. The company appears to be overvalued given its current price of $1.65, especially when considering its negative P/E ratio due to being loss-making, a Price to Book Value of 1.74, and an extraordinarily high ROCE of 295.01%, which is not sustainable. In comparison to its peers, Soligenix's EV to EBITDA stands at 0.09, while Inhibikase Therapeutics, Inc. has a similar valuation grade with an EV to EBITDA of -0.9168, and Aileron Therapeutics, Inc. shows an EV to EBITDA of -1.2239. These comparisons suggest that Soligenix is not only struggling relative to its industry but also lacks the financial metrics to justify its current valuation. Overall, the analysis indicates that Soligenix, Inc. is overvalued in the current market context.

Q: Is Soligenix, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Soligenix, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, indicating positive momentum. The daily moving averages are bullish, supporting the upward trend. However, the Bollinger Bands show a mildly bullish stance on the weekly chart but bearish on the monthly, suggesting mixed signals. The KST is bullish on the weekly and mildly bullish on the monthly, while the OBV is mildly bearish on the weekly, indicating some selling pressure. Overall, the technical stance is mildly bullish, but caution is warranted due to the mixed indicators.In terms of performance, Soligenix has underperformed the S&P 500 across multiple periods, with a 1-month return of -44.35% compared to the S&P 500's 2.33%, and a 1-year return of -31.17% versus the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

77.08 k

Shareholding (Dec 2025)

FII

0.97%

Held by 4 FIIs

DII

97.92%

Held by 1 DIIs

Promoter

0.00%

How big is Soligenix, Inc.?

22-Jun-2025

As of Jun 18, Soligenix, Inc. has a market capitalization of 5.88 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -9.59 million over the latest four quarters.

View full answer

What does Soligenix, Inc. do?

22-Jun-2025

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing treatments for rare diseases, with a market cap of $5.88 million and a recent net profit of -$3 million. The company has no dividend yield and is currently loss-making.

View full answer

Who are in the management team of Soligenix, Inc.?

22-Jun-2025

As of March 2022, the management team of Soligenix, Inc. includes Dr. Christopher Schaber as Chairman, President, and CEO, along with independent directors Mr. Gregg Lapointe, Ms. Diane Parks, Dr. Robert Rubin, and Dr. Jerome Zeldis.

View full answer

Is Soligenix, Inc. overvalued or undervalued?

25-Jun-2025

As of August 13, 2021, Soligenix, Inc. is considered overvalued at $1.65 due to its negative P/E ratio, high Price to Book Value of 1.74, and unsustainable ROCE of 295.01%, especially when compared to peers with worse EV to EBITDA ratios.

View full answer

Is Soligenix, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Soligenix, Inc. shows a mildly bullish technical trend with positive momentum indicators, but it has underperformed the S&P 500 significantly over the past month and year.

View full answer

Compare Soligenix, Inc. with Similar Stocks

Fresh Tracks Therapeutics, Inc.DMK Pharmaceuticals Corp.Processa Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 12 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.37

Return on Equity

-154.03%

Price to Book

1.63

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-72.73%

6 Months

-77.5%

1 Year

-84.36%

2 Years

-95.19%

3 Years

-71.98%

4 Years

-99.75%

5 Years

-75.92%

Soligenix, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

4.37%

EBIT to Interest (avg)

-12.01

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.00

Sales to Capital Employed (avg)

0.03

Tax Ratio

3.79%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

4.75%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.63

EV to EBIT

-0.16

EV to EBITDA

-0.16

EV to Capital Employed

-0.71

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-154.03%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (1.11%)

Foreign Institutions

Held by 4 Foreign Institutions (0.97%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -16.00% vs 7.41% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.50",
          "val2": "-2.60",
          "chgp": "-34.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.90",
          "val2": "-2.50",
          "chgp": "-16.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -33.73% vs -36.07% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.80",
          "val2": "-9.60",
          "chgp": "-22.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.60",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.10",
          "val2": "-8.30",
          "chgp": "-33.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.50

-2.60

-34.62%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.90

-2.50

-16.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -16.00% vs 7.41% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.80

-9.60

-22.92%

Interest

0.00

Exceptional Items

0.00

0.60

-100.00%

Consolidate Net Profit

-11.10

-8.30

-33.73%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -33.73% vs -36.07% in Dec 2024

All Annual Results

Company CV

About Soligenix, Inc.

Soligenix, Inc.

Pharmaceuticals & Biotechnology

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two business segments: Specialized BioTherapeutics and Public Health Solution. Soligenix’s Specialized BioTherapeutics business segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma (CTCL). The Public Health Solutions business segment includes active development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious disease. CTCL is its innate defense regulator technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Company Coordinates

Company Details

29 Emmons Dr Ste B10 , PRINCETON NJ : 08540-5950

Tel: 1 609 5388200

https://www.soligenix.com/

Registrar Details